Login / Signup
Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
Hayase Hakariya
Mutsuko Ohnishi
Tetsuya Tanimoto
Published in:
Diabetes, obesity & metabolism (2024)
Keyphrases
</>
weight loss
bariatric surgery
healthcare
public health
health insurance
mental health
roux en y gastric bypass
affordable care act
gastric bypass
health information
health promotion
adverse drug
emergency department
type diabetes
drug induced
skeletal muscle
glycemic control